Carcinoma avanzado de tiroides: Nuevas opciones terapéuticas

Agustín Falco

doi:10.56969/oc.v20i1.105

Autores/as

Agustín Falco Instituto Alexander Fleming, Buenos Aires https://orcid.org/0000-0003-4487-2444

DOI:

https://doi.org/10.56969/oc.v20i1.105

Palabras clave:

terapia dirigida, carcinoma avanzado de tiroides, inhibidores tirosin-kinasa, targeted therapy, advanced thyroid cancer, tyrosine kinase inhibitors

Resumen

El carcinoma avanzado de tiroides se muestra como una enfermedad quimiorresistente una vez refractaria al radioiodo. En este contexto, el desarrollo de nuevas moléculas es fundamental. Diferentes ensayos clínicos sugieren el beneficio de distintos inhibidores tirosin-kinasa y antiangiogénicos, entre ellos los recientemente aprobados vandetanib y cabozantinib. Resumiremos aquí los resultados respecto de eficacia y toxicidad de estos trabajos, como así también las nuevas moléculas que se encuentran en desarrollo y estudio en esta enfermedad.

Citas

Deshpande H, Gettinger S, Sosa JA. Axitinib.The evidence of its potential in the treatment of advanced thyroid cancer. Core Evid 2010; 4: 43-8. DOI: https://doi.org/10.2147/CE.S5996

Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006; 6: 292-306. DOI: https://doi.org/10.1038/nrc1836

Moo-Young TA, Traugott AL, Moley JF. Sporadic and familial medullary thyroid carcinoma: state of the art. Surg Clin North Am 2009; 89: 1193-204. DOI: https://doi.org/10.1016/j.suc.2009.06.021

Leboullex S, Baudin E, Travagli JP, Schlumberger M. Medullary thyroid carcinoma. Clin Endocrinol (Oxf) 2004; 61: 299-310. DOI: https://doi.org/10.1111/j.1365-2265.2004.02037.x

Patel KN, Shaha AR. Poorly differentiated and anaplastic thyroid cancer. Cancer Control 2006; 13: 119-28. DOI: https://doi.org/10.1177/107327480601300206

DrozJP,SchlumbergerM,RougierP,GhosnM,GardetP, Parmentier C. Chemotherapy in metastatic non anaplastic thyroid cancer: experience at the Institut Gustave-Roussy. Tumori 1990; 76: 480-3. DOI: https://doi.org/10.1177/030089169007600513

Argiris A, Agarwala SS, Karamouzis MV, Burmeister LA, Carty SE. Aphase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer. Invest New Drugs 2008; 26: 183-8. DOI: https://doi.org/10.1007/s10637-007-9091-2

Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009; 27: 1675-84. DOI: https://doi.org/10.1200/JCO.2008.18.2717

Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008; 26: 4714-9. DOI: https://doi.org/10.1200/JCO.2008.16.3279

Brose M, Nutting C, Jarzab B, et al. Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial. J Clin Oncol 2013; 31: (suppl; abstr 4). DOI: https://doi.org/10.1200/jco.2013.31.18_suppl.4

Hoffmann S, Gläser S, Wunderlich A, et al. Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors: a novel antiproliferative/antiangiogenic strategy in thyroid cancer. Langenbecks Arch Surg 2006; 391: 589-96. DOI: https://doi.org/10.1007/s00423-006-0104-y

Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012; 30:134-41. DOI: https://doi.org/10.1200/JCO.2011.35.5040

Schoffski P, Elissi R, Müller S, et al. An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. J Clin Oncol 2012; 30: (suppl; abstr 5508). DOI: https://doi.org/10.1200/jco.2012.30.15_suppl.5508

Ravaud A, de la Fouchardière C, Courbon F, et al. Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial. J Clin Oncol 2008; 26: 6058. DOI: https://doi.org/10.1200/jco.2008.26.15_suppl.6058

Cohen EE, Needles BM, Cullen KJ, et al. Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol 2008; 26: 6025. DOI: https://doi.org/10.1200/jco.2008.26.15_suppl.6025

Sherman SI, Wirth LJ, Droz JP, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008; 359: 31-42. DOI: https://doi.org/10.1056/NEJMoa075853

Bible KC, Smallridge RC, Maples WJ, et al. Phase II trial of pazopanib in progressive, metastatic, iodine-insensitive differentiated thyroid cancers. Proc Am Soc Clin Oncol 2009; 27: 3521. DOI: https://doi.org/10.1200/jco.2009.27.15_suppl.3521

Bible KC, Suman VJ, Molina JR, et al. A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. J Clin Endocrinol Metab 2014; 99:1687-93. DOI: https://doi.org/10.1200/jco.2014.32.15_suppl.6026

Schlumberger M, Tahara M, Wirth LJ, et al. A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT). J Clin Oncol 2014; 32: 5s (suppl; abstr LBA6008). DOI: https://doi.org/10.1200/jco.2014.32.15_suppl.lba6008

Hong D, Camacho L, Ng C, et al. Phase I study of tipifarnib and sorafenib in patients with biopsiable advanced cancers. Proc Am Soc Clin Oncol 2007; 25: (18S): 3549. DOI: https://doi.org/10.1200/jco.2007.25.18_suppl.3549

Dowlati A, Robertson K, Cooney M, et al. A phase I pharmacokinetic and translational study of thenovel vascular targeting agent combretastatin a-4 phosphate on a single- dose intravenous schedule in patients with advanced cancer. Cancer Res 2002; 62: 3408-16.

CooneyMM,SavvidesP,AgarwalaS,etal.PhaseIIstudy of combrestatin A4 phosphate (CA4P) in patients with advanced anaplastic thyroid carcinoma (ATC). J Clin Oncol 2006; 24: 5580. DOI: https://doi.org/10.1200/jco.2006.24.18_suppl.5580